Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORA-JAPAN: Characteristics and prescription patterns of doravirine-based regimens in people living with HIV in Japan
jRCT1030250308Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Demographic and clinical characteristics, Concomitant antiretrovirals with doravirine and 1 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT1030250308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030250308.